PA
BNR

Perceptive Advisors’s Burning Rock Biotech BNR Stock Holding History

Perceptive Advisors’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,000
Closed -$3.46M – 145
2020
Q4 		$3.46M Hold
15,000
– – 0.04% 127
2020
Q3 		$3.76M Hold
15,000
– – 0.05% 107
2020
Q2 		$4.05M Buy
+15,000
New +$4.11M 0.07% 98

Other funds holding BNR

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors's BNR Position: Q1 2021 in Review

Perceptive Advisors sold out of Burning Rock Biotech (BNR) in Q1 2021, closing a stake of 15,000 shares — an estimated $3.46M sold.

Perceptive Advisors first reported a position in BNR in Q2 2020 and held it in 3 quarters. The position peaked at $4.05M in Q2 2020. 54 funds tracked by Wall St. Rank hold BNR as of Q1 2021.

  • Perceptive Advisors reported no remaining Burning Rock Biotech position as of Q1 2021 after selling out during the quarter.
  • Perceptive Advisors sold 15,000 Burning Rock Biotech shares in Q1 2021, an estimated $3.46M.
  • Perceptive Advisors first reported a position in Burning Rock Biotech in Q2 2020 and held it in 3 quarters.
  • Perceptive Advisors's Burning Rock Biotech position peaked at $4.05M in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q1 2021.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.